Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder: An Open-Label Trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
To the Editor: Most obsessive-compulsive disorder (OCD) patients treated with serotonin reuptake inhibitors (SRIs) show only partial reduction of symptoms.1 Data suggest that OCD may be caused in part by glutamatergic dysfunction in orbitofrontal/basal ganglia brain circuits, 2,3 and prior trials of glutamate modulators (eg, riluzole, memantine) given as augmentation to SRIs suggest that from 30% to 54% of OCD patients respond.[4][5][6][7][8] We conducted a 12-week, prospective, open-label study to assess whether SRI augmentation with minocycline, a tetracycline derivative with putative glutamate-modulating activity (ie, enhancing glial glutamate transport) 9 in addition to its antibiotic properties, would improve OCD symptoms.Advantages of minocycline include low cost (riluzole is expensive) and US Food and Drug Administration (FDA) approval in adults and children > 12 years (memantine is FDA approved only in adults).Minocycline is the most widely prescribed antibiotic for chronic acne because its antibiotic resistance is lower than those of other tetracyclines and antimicrobials.10 It has an excellent side
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toward a neurobiology of obsessive-compulsive disorder
Graybiel, A. M., & Rauch, S. L. (2000) · Neuron · doi:10.1016/s0896-6273(00)00113-6 · Cited by 864
Meta-analysis of the symptom structure of obsessive–compulsive disorder
Bloch, M. H., Landeros-Weisenberger, A., Rosario, M. C., Pittenger, C., & Leckman, J. F. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020320 · Cited by 681
Adults with early-onset obsessive-compulsive disorder
do Rosario-Campos, M. C., Leckman, J. F., Mercadante, M. T., Shavitt, R. G., Prado, H. D. S., Sada, P., Zamignani, D., & Miguel, E. C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1899 · Cited by 373
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Baptiste, D. C., Hartwick, A. T. E., Jollimore, C. A. B., Baldridge, W. H., Seigel, G. M., & Kelly, M. E. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001081 · Cited by 55
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“…humoral immunity abnormalities in subgroups of schizophrenia patients — as evidenced by increased B cell counts [21,76], increased production of autoantibodies including antiviral antibodies [76] and increased immunoglobulin E [52] — adds further support to the Th2 response dominance hypothesis.”
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Self-citationBandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., Cinosi, E., Davies, S., Domschke, K., Fineberg, N., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1190867 · Cited by 347
“Although only few studies have reported positive results for the efficacy of anti-inflammatory drug treatment on anxiety disorders (Rodriguez et al. 2010; Sayyah et al. 2011), such results do illustrate the proinflammatory nature of anxiety disorders.”
Minocycline: Therapeutic Potential in Psychiatry
Dean, O. M., Data-Franco, J., Giorlando, F., & Berk, M. (2012) · CNS Drugs · doi:10.2165/11632000-000000000-00000 · Cited by 131
“However, the authors suggest that minocycline may have more therapeutic potential in those with primary hoarding or early onset of the disorder.([82]) Given the central role glutamate dysfunction (and associated excitotoxicity) plays in addiction,([18]) there is early evidence suggesting minocycline, which has effects…”
Background
Metadata
- Authors
- Rodriguez, C. I., Bender, J., Marcus, S. M., Snape, M., Rynn, M., & Simpson, H. B.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-09-15
- Volume
- 71
- Issue
- 09
- Pages
- 1247-1249
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2037258739
- Cited by
- 56
- References
- 6
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.